US Pharma MarketingASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline message, detailed results from ivonescimab’s chemo-combo readout in first-line lung cancer are being picked apart by a critical pair of eyes. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation…
Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline message, detailed results from ivonescimab’s chemo-combo readout in first-line lung cancer are being picked apart by a critical pair of eyes.
Source: FierceBiotech